Coronavirus / COVID

Rebecca Bromley-Dulfano, MS, says expanding access to home testing and virtual care is key to closing racial gaps in treatment.

Invivyd forms the SPEAR Study Group to evaluate pemivibart for Long COVID and post-vaccine syndrome, exploring monoclonal antibody treatment of spike protein.

Six health organizations and a physician challenge the legality of rescinded vaccine recommendations and dismissal of federal advisory members.

Results from Invivyd’s pemivibart (Pemgarda) phase 3 trial show it had a significant PrEP effect during the 6-month on-drug period for both immunocompromised and immunocompetent populations.

New epidemiologic data, vaccine effectiveness, and safety assessments guide a move from universal to targeted vaccination recommendations for the 2025–26 season.

Although COVID-19 has receded quite a bit from the minds of many, it still remains a virus that can present serious morbidity and mortality. Here is a review of clinical treatment strategies by an intensivist when seeing patients with severe COVID-19.

Phase 3 results show immune response and tolerability in adults 65 and older, following phase 2 findings.

The company's vaccine, mRNA-1283, becomes the first approval under the new federal guidelines.

The World Health Organization (WHO) says the previously predominant LP81 variant has been declining, and that the NB181 strain, which is a variant under monitoring, is increasing.

Following a positive safety review, Vaxart advances its needle-free, room-temperature stable oral vaccine candidate with government-backed funding and a year-long follow-up study.

In a joint announcement, the leaders of the NIH, HHS, and FDA, made comments about this CDC immunization removal.

The FDA committee advisors are recommending the monovalent JN1-lineage-based COVID-19 vaccines preferentially using the LP81 strain.

The company made the decision after the FDA requested more vaccine data for the mRNA-1083 vaccine. Moderna plans to resubmit their Biologics License Application (BLA) for the vaccine later this year.

FDA leadership says they expect more testing for COVID-19 vaccines and that they generate antibody titers in people in order for vaccines to be considered for approval.

The company's Nuvaxovid vaccine is the only recombinant protein-based, non-mRNA COVID-19 immunization available in the US.

More than 80% of adults support COVID-19 vaccination, but hesitancy linked to side effects, geopolitics, and misinformation remains a challenge, says lead researcher Mahmud Sheku, MPH, MSc.

Clinical-stage company, Biovie, will study its therapy, bezisterim, for treatment of neurological symptoms associated with the condition. The company expects to have study results in the first half of 2026.

In a large study, Moderna’s investigational vaccine, mRNA-1083, was shown to have noninferiority to other vaccines, and had an acceptable tolerability and safety profile.

Three different studies reveal blood signatures linked to symptoms, immune pathways tied to lung damage, and the efficacy of cognitive training for brain fog.

The company had requested approval for its mRNA-1083 combination vaccine last year. With this setback, the company is now looking at 2026 for approval.

Novavax Vice President Matthew Rousculp on reactogenicity, vaccine hesitancy, and supporting informed decisions.

Matthew Hepburn, MD, offers some insights on his time as vaccine development lead for Operation Warp Speed and the ability to develop a COVID-19 vaccine within a year.

At ESCMID Global 2025, SHIELD study data show Novavax recipients experienced fewer adverse effects and missed less work compared with those who received the Pfizer-BioNTech COVID-19 vaccine.

After delays in the review of the COVID-19 vaccine—which missed its April 1 review deadline—the agency has requested new data.

The University of California San Francisco and Gladstone Institutes develop compounds with a 1,000,000-fold reduction in viral titers and 1000 times effective concentration in the brain.